Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized Study of Cetuximab (Erbitux™, C225) and Best Supportive Care Versus Best Supportive Care in Patients With Pretreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Positive Colorectal Carcinoma
Brief Summary: RATIONALE: Monoclonal antibodies, such as cetuximab, can target tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Best supportive care is the use of drugs and other treatments to improve the quality of life of patients. Combining cetuximab with best supportive care may slow the growth of the tumor and help patients live longer and more comfortably. It is not yet known whether cetuximab combined with best supportive care is more effective than best supportive care alone in treating metastatic epidermal growth factor receptor-positive colorectal cancer.

PURPOSE: This randomized phase III trial is studying cetuximab and best supportive care to see how well they work compared to best supportive care alone in treating patients with metastatic epidermal growth factor receptor-positive colorectal cancer.


Options:
A: Arm Label: Safety part: EMD 525797 250 mg + Standard of Care (SoC); Type: EXPERIMENTAL; Interventions: Drug: EMD 525797 250 mg, Drug: Cetuximab, Drug: Irinotecan | Arm Label: Safety part: EMD 525797 500 mg + SoC; Type: EXPERIMENTAL; Interventions: Drug: EMD 525797 500 mg, Drug: Cetuximab, Drug: Irinotecan | Arm Label: Safety part: EMD 525797 750 mg + SoC; Type: EXPERIMENTAL; Interventions: Drug: EMD 525797 750 mg, Drug: Cetuximab, Drug: Irinotecan | Arm Label: Safety part: EMD 525797 1000 mg + SoC; Type: EXPERIMENTAL; Interventions: Drug: EMD 525797 1000 mg, Drug: Cetuximab, Drug: Irinotecan | Arm Label: Randomized part: EMD 525797 500 mg + SoC; Type: EXPERIMENTAL; Interventions: Drug: EMD 525797 500 mg, Drug: Cetuximab, Drug: Irinotecan | Arm Label: Randomized Part: EMD 525797 1000 mg + SoC; Type: EXPERIMENTAL; Interventions: Drug: EMD 525797 1000 mg, Drug: Cetuximab, Drug: Irinotecan | Arm Label: Randomized Part: SoC; Type: OTHER; Interventions: Drug: Cetuximab, Drug: Irinotecan | Intervention Type: DRUG; Name: EMD 525797 250 mg; Assigned to Arm(s): Safety part: EMD 525797 250 mg + Standard of Care (SoC) | Intervention Type: DRUG; Name: EMD 525797 500 mg; Assigned to Arm(s): Randomized part: EMD 525797 500 mg + SoC, Safety part: EMD 525797 500 mg + SoC | Intervention Type: DRUG; Name: EMD 525797 750 mg; Assigned to Arm(s): Safety part: EMD 525797 750 mg + SoC | Intervention Type: DRUG; Name: EMD 525797 1000 mg; Assigned to Arm(s): Randomized Part: EMD 525797 1000 mg + SoC, Safety part: EMD 525797 1000 mg + SoC | Intervention Type: DRUG; Name: Cetuximab; Assigned to Arm(s): Randomized Part: EMD 525797 1000 mg + SoC, Randomized Part: SoC, Randomized part: EMD 525797 500 mg + SoC, Safety part: EMD 525797 1000 mg + SoC, Safety part: EMD 525797 250 mg + Standard of Care (SoC), Safety part: EMD 525797 500 mg + SoC, Safety part: EMD 525797 750 mg + SoC | Intervention Type: DRUG; Name: Irinotecan; Assigned to Arm(s): Randomized Part: EMD 525797 1000 mg + SoC, Randomized Part: SoC, Randomized part: EMD 525797 500 mg + SoC, Safety part: EMD 525797 1000 mg + SoC, Safety part: EMD 525797 250 mg + Standard of Care (SoC), Safety part: EMD 525797 500 mg + SoC, Safety part: EMD 525797 750 mg + SoC
B: Arm Label: FOLFIRI + Ramucirumab; Type: EXPERIMENTAL; Interventions: Biological: Ramucirumab, Drug: Irinotecan, Drug: Folinic Acid, Drug: 5-Fluorouracil | Arm Label: FOLFIRI + Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Drug: Irinotecan, Drug: Folinic Acid, Drug: 5-Fluorouracil | Intervention Type: BIOLOGICAL; Name: Ramucirumab; Assigned to Arm(s): FOLFIRI + Ramucirumab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): FOLFIRI + Placebo | Intervention Type: DRUG; Name: Irinotecan; Assigned to Arm(s): FOLFIRI + Placebo, FOLFIRI + Ramucirumab | Intervention Type: DRUG; Name: Folinic Acid; Assigned to Arm(s): FOLFIRI + Placebo, FOLFIRI + Ramucirumab | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): FOLFIRI + Placebo, FOLFIRI + Ramucirumab
C: Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A
D: Arm Label: Panitumumab plus best supportive care; Type: EXPERIMENTAL; Interventions: Drug: Panitumumab | Arm Label: Best Supportive Care; Type: OTHER; Interventions: Other: Best supportive care | Intervention Type: OTHER; Name: Best supportive care; Assigned to Arm(s): Best Supportive Care | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): Panitumumab plus best supportive care

Answer: C